Pharmaceutical company MSD (known as Merck & Co. in the United States and Canada) has announced an expansion of its human papillomavirus (HPV) vaccine access program in Africa. The initiative aims to broaden vaccination to include boys and older women, and to improve access to broader cancer treatment options, with a focus on strengthening private-sector partnerships with governments, insurers, and health organizations.
The expansion is part of a growing push to curb cervical cancer deaths on the continent. Cervical cancer is a leading cause of cancer-related deaths among women in many African countries, and HPV vaccination is a proven preventive measure. The World Health Organization has set a target to eliminate cervical cancer as a public health problem.
MSD's strategy involves working with local partners to overcome barriers to vaccine access, which can include cost, supply chain logistics, and healthcare infrastructure. The company's Gardasil 9 vaccine protects against nine HPV types responsible for the majority of cervical cancers and other HPV-related diseases.
This move aligns with broader global health efforts to increase HPV vaccination coverage, particularly in low- and middle-income countries where the burden of cervical cancer is highest. The success of the initiative will depend on the effectiveness of the public-private partnerships in delivering sustainable vaccination programs.
